Patient info Open main menu

Neoclarityn® 5 mg film-coated tablets – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
5 mg
Other strengths and forms:
Contains active substance:

Patient leaflet - Neoclarityn 5 mg film-coated tablets

1. What Neoclarityn is and what it is used for What Neoclarityn is

Neoclarityn contains desloratadine which is an antihistamine. How Neoclarityn works

Neoclarityn is an antiallergy medicine that does not make you drowsy. It helps control your allergic reaction and its symptoms.

When Neoclarityn should be used

Neoclarityn relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older. These symptoms include sneezing, runny or itchy nose, itchy palate, and itchy, red or watery eyes.

Neoclarityn is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy). These symptoms include itching and hives.

Relief of these symptoms lasts a full day and helps you to resume your normal daily activities and sleep.

2. What you need to know before you take Neoclarityn

Do not take Neoclarityn

  • if you are allergic to desloratadine, or any of the other

    ingredients of this medicine (listed in section 6) or to loratadine.

Warnings and precautions

Talk to your doctor, pharmacist or nurse before taking Neoclarityn:

  • if you have poor kidney function.
  • if you have medical or familial history of seizures. Children and adolescents

Do not give this medicine to children less than 12 years of age.

Other medicines and Neoclarityn

There are no known interactions of Neoclarityn with other medicines.

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Neoclarityn with food, drink and alcohol

Neoclarityn may be taken with or without a meal. Use caution when taking Neoclarityn with alcohol. Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, or pharmacist for advice before taking this medicine. Taking Neoclarityn is not recommended if you are pregnant or nursing a baby.

There is no data available on male/female fertility. Driving and using machines

At the recommended dose, this medicine is not expected to affect your ability to drive or use machines. Although most people do not experience drowsiness, it is recommended not to engage in activities requiring mental alertness, such as driving a car or operating machinery until you have established your own response to the medicine.

Neoclarityn tablet contains lactose

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

3. How to take Neoclarityn

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Use in adults and adolescents 12 years of age and over

The recommended dose is one tablet once a day with water, with or without food.

This medicine is for oral use.

Swallow the tablet whole.

Regarding the duration of treatment, your physician will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Neoclarityn. If your allergic rhinitis is intermittent (presence of symptoms for less than 4 days per week or for less than 4 weeks), your physician will recommend you a treatment schedule that will depend on the evaluation of the history of your disease. If your allergic rhinitis is persistent (presence of symptoms for 4 days or more per week and for more than 4 weeks), your physician may recommend you a longer term treatment. For urticaria, the duration of treatment may be variable from patient to patient and therefore you should follow the instructions of your physician.

If you take more Neoclarityn than you should

Take Neoclarityn only as it is prescribed for you. No serious problems are expected with accidental overdose. However, if you take more Neoclarityn than you were told to, tell your doctor, pharmacist or nurse immediately.

If you forget to take Neoclarityn

If you forget to take your dose on time, take it as soon as possible and then go back to your regular dosing schedule. Do not take a double dose to make up for a forgotten dose. If you stop taking Neoclarityn

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

During the marketing of Neoclarityn, cases of severe allergic reactions (difficulty in breathing, wheezing, itching, hives and swelling) have been reported very rarely. If you notice any of these serious side effects, stop taking the medicine and seek urgent medical advice straight away.

In clinical studies with Neoclarityn, the following side effects were reported as:

Common: the following may affect up to 1 in 10 people

  • fatigue
  • dry mouth
  • headache

During the marketing of Neoclarityn, the following side effects were reported as:

Very rare: the following may affect up to 1 in 10,000 people

  • severe allergic reactions
  • rash
  • pounding or irregular heartbeat
  • fast heartbeat
  • stomach ache
  • feeling sick (nausea)

    • vomiting
    • upset stomach
    • diarrhoea
    • dizziness
    • drowsiness
    • inability to sleep
    • muscle pain
    • hallucinations
    • seizures
    • restlessness with increased body movement
    • liver inflammation
    • abnormal liver function tests

Not known: frequency cannot be estimated from the available data

  • unusual weakness
  • yellowing of the skin and/or eyes
  • increased sensitivity of the skin to the sun, even in case of hazy sun, and to UV light, for instance to UV lights of a solarium
  • changes in the way the heart beats
  • abnormal behaviour
  • aggression
  • weight increased, increased appetite

Children

Not known: frequency cannot be estimated from the available data

  • slow heartbeat
  • change in the way the heart beats
  • abnormal behaviour
  • aggression

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Neoclarityn

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

Do not store above 30°C. Store in the original package. Do not use this medicine if you notice any change in the appearance of the tablets.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Neoclarityn contains

  • The active substance is desloratadine 5 mg
  • The other ingredients of the tablet are calcium hydrogen phosphate dihydrate, microcrystalline cellulose, maize starch, talc. Tablet coating contains film coat (containing lactose monohydrate (see section 2 “Neoclarityn tablet contains lactose”), hypromellose, titanium dioxide, macrogol 400, indigotin (E132)), clear coat (containing hypromellose, macrogol 400), carnauba wax, white wax. What Neoclarityn looks like and contents of the pack

Neoclarityn 5 mg film-coated tablets are packed in blisters in packs of 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50 or 100 tablets. Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder: Organon Pharma (UK) Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom.

Manufacturer: Organon Heist bv, Industriepark 30, 2220 Heist-op-den-Berg, Belgium.

For any information about this medicine, please contact: Organon Pharma (UK) Limited

medicalinformationuk@organon.com

This leaflet was last revised in October 2024.

© 2024 Organon group of companies. All rights reserved. PIL.NEO-CLR-TAB.24.UK.0402.61-3-WF.NoRCN

TIN10GR/V

05

120224

282mm x 335mm Folding size 48x85 403919146-0020

6000595300

N/A

N/A

6000595300

311024-1

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PLGB 00025/0650

Last revision stated in the text: October 2024 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Neoclarityn 5 mg film-coated tablets

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Desloratadine
Strength 5 mg
Pharmaceutical form Oral tablet
How is it taken Oral
Excipients calcium hydrogen phosphate dihydrate, microcrystalline cellulose, maize starch, talc, clear coat (containing hypromellose, macrogol 400), carnauba wax, white wax.
Pack sizes 30 tablet
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 2 years
Storage Do not store above 30°C.
Store in the original package.
Drug group (ATC) Antihistamines – H1 antagonist
  1. R Respiratory system drugs
    1. R06 Antihistamines for systemic use
      1. R06A Antihistamines for systemic use
        1. R06AX Other antihistamines for systemic use
          1. R06AX27 desloratadine
Marketing authorisation PLGB 00025/0650 (first authorised 1 January 2021)
Marketing authorisation holder Organon Pharma (UK) Limited
Codes GTIN 0840164507041, 0840164527476 · BNF 03040100

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.